Pregnancy-associated progenitor cells: an under-recognized potential source of stem cells in maternal lung

Abstract

Novel therapies are needed for the treatment of acute and chronic lung diseases, many of which are incurable. The use of exogenous stem cells has shown promise in both animal models and clinical trials. However, to date, the stem cell literature has under-recognized naturally acquired pregnancy-associated progenitor cells (PAPCs). These cells are found at sites of injury or disease in female tissues. They persist for decades after parturition in maternal blood and organs, with the largest number being found in the maternal lungs. Their presence there may be one explanation for the sex differences observed in the prevalence and prognosis of some lung diseases. Although the clinical significance of these cells is as yet unknown, the literature suggests that some of the PAPCs are stem cells or have stem cell-like properties. PAPCs harvested from the blood or organs of parous women could potentially be used as an alternate source of cells with regenerative properties for the woman herself or her children. Because PAPCs preferentially traffic to the maternal lung they may play a significant role in recovery or protection from lung disease. In this review article, we discuss ongoing research investigating the administration of both adult and placenta-derived stem cells to treat lung disease, and how PAPCs may also play an important future therapeutic role.

Figure 1

Fetal cells expressing the green fluorescent protein (GFP) transgene are clearly visible within the murine maternal lung at gestational day 18. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole. Left: 400×, Right: 1000× magnification.

Figure 1

Fetal cells expressing the green fluorescent protein (GFP) transgene are clearly visible within the murine maternal lung at gestational day 18. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole. Left: 400×, Right: 1000× magnification.